Dr. J. Joseph Kim, Inovio's President and CEO, said, "In 2012 our DNA vaccines achieved two vital breakthroughs in human studies: best-in-class therapeutic immune responses displayed the desired killing effect against a targeted disease; broadly targeted universal vaccines generated protective immune responses against multiple unmatched strains of a pathogen. These were scientific firsts. Our current funding will carry us through additional important milestones, including efficacy data from our cervical dysplasia phase II study in Q1 2014."
Look at what HTVN said about the HiV study. They said that they had not seen such immune responses in HIV since 15 years ago. INO is on the verge of a high therapeutic rate with HIV. Glaxosmithkline and Gilead science will not be happy with this!
If good news is on the way lets say monday or tues and insiders have this knowledge and have bought today, wouldnt this be considered insider trading? Or is bad news on the way and they are buying small amounts just to throw us off? Would like to hear what you guys have to think on this...
sticktheyj42, for some reason I can't reply directly to your post...So, IMHO
Likely these insiders buys are irrelevant with the very short term news and stock's behavior.
Insiders believe that a $0.55 is a good price to buy and they don't intend to sell these shares next week.
As for the results, they could be positive, negative or mixed. If Chronvac results are negative, it doesn't mean that Pennvax will be negative also. Longs here believe to the strong possibility that among INO's wide pipeline will be some further successful trials, if not all. Our estimate is based in the very positive clinical trials until now.
Bottom line, insiders do believe in this company and have bought at this price level not necessarily for the short term. Institutional investors with deep knowledge of the sector have bought at the same price also. Short term traders must not depend their decisions to buy this stock on this info though.